Table 1 Demographic and clinical characteristics of patients with Crohn’s disease at baseline
Variable | Total | Inland city | Coastal city | P value |
|---|---|---|---|---|
N (%) | 499 | 191 (38.3%) | 308 (61.7%) | |
Age at enrollment (years), mean (SD) | 32.3 (11.43) | 34.3 (13.03) | 31.1 (10.14) | 0.0022 |
Male, n (%) | 348 (69.7%) | 138 (72.3%) | 210 (68.2%) | |
Ethnicity, n (%) | ||||
Chinese Han | 495 (99.2%) | 187 (97.9%) | 308 (100.0%) | |
Other Chinese minority | 4 (0.8%) | 4 (2.1%) | 0 | |
BMI (kg/m2), mean (SD) | 19.10 (3.198) | 18.80 (2.676) | 19.29 (3.479) | |
Nicotine use history, n (%) | 0.0036 | |||
N | 442 | 165 | 277 | |
Never used | 382 (86.4%) | 132 (80.0%) | 250 (90.3%) | |
Current user | 36 (8.1%) | 17 (10.3%) | 19 (6.9%) | |
Former user | 24 (5.4%) | 16 (9.7%) | 8 (2.9%) | |
Alcohol use history, n (%) | 0.0023 | |||
N | 443 | 166 | 277 | |
Never used | 401 (90.5%) | 143 (86.1%) | 258 (93.1%) | |
Current user | 22 (5.0%) | 8 (4.8%) | 14 (5.1%) | |
Former user | 20 (4.5%) | 15 (9.0%) | 5 (1.8%) | |
Medical history reported, n (%) | ||||
Any medical history | 180 (36.1%) | 76 (39.8%) | 104 (33.8%) | |
Hepatitis B | 19 (3.8%) | 7 (3.7%) | 12 (3.9%) | |
Appendicitis | 10 (2.0%) | 5 (2.6%) | 5 (1.6%) | |
Hypertension | 8 (1.6%) | 3 (1.6%) | 5 (1.6%) | |
Nephrolithiasis | 10 (2.0%) | 7 (3.7%) | 3 (1.0%) | |
CD-related surgery history, n (%) | 119 (23.8%) | 51 (26.7%) | 68 (22.1%) | 0.2071 |
Perianal disease related surgery, n (%) | 79 (15.8%) | 21 (11.0%) | 58 (18.8%) | 0.0023 |
Family history of IBD, n (%) | ||||
N | 6 | 2 | 4 | |
Crohn’s disease | 5 (83.3%) | 2 (100%) | 3 (75.0%) | |
Ulcerative colitis | 1 (16.7%) | 0 | 1 (25.0%) | |
Age at disease onset (years), n (%) | 0.0291 | |||
≤ 16 | 29 (5.8%) | 15 (7.9%) | 14 (4.5%) | |
17–39 | 401 (80.4%) | 142 (74.3%) | 259 (84.1%) | |
≥ 40 | 69 (13.8%) | 34 (17.8%) | 35 (11.4%) | |
Age at initial diagnosis (years), n (%) | 0.0083 | |||
≤ 16 | 6 (1.2%) | 4 (2.1%) | 2 (0.6%) | |
17–39 | 418 (83.8%) | 148 (77.5%) | 270 (87.7%) | |
≥ 40 | 75 (15.0%) | 39 (20.4%) | 36 (11.7%) | |
Time from disease onset to initial diagnosis (months), mean (SD) | 32.0 (46.43) | 39.9 (58.84) | 27.0 (35.93) | 0.0255 |
Location, n (%) | < 0.0001 | |||
N | 493 | 190 | 303 | |
L1 | 137 (27.8%) | 69 (36.3%) | 68 (22.4%) | |
L2 | 71 (14.4%) | 38 (20.0%) | 33 (10.9%) | |
L3 | 277 (56.2%) | 82 (43.2%) | 195 (64.4%) | |
L4 | 8 (1.6%) | 1 (0.5%) | 7 (2.3%) | |
Behavior, n (%) | < 0.0001 | |||
N | 495 | 190 | 305 | |
B1 | 247 (49.9%) | 110 (57.9%) | 137 (44.9%) | |
B2 | 148 (29.9%) | 45 (23.7%) | 103 (33.8%) | |
B3 | 100 (20.2%) | 35 (18.4%) | 65 (21.3%) | |
Perianal disease | 144 (29.1%) | 32 (16.8%) | 112 (36.7%) | |
Crohn’s Disease Activity Index at baseline, n (%) | 0.0094 | |||
N | 165 | 80 | 85 | |
< 150 | 81 (49.1%) | 37 (46.3%) | 44 (51.8%) | |
150–220 | 43 (26.1%) | 28 (35.0%) | 15 (17.6%) | |
221–400 | 39 (23.6%) | 13 (16.3%) | 26 (30.6%) | |
> 400 | 2 (1.2%) | 2 (2.5%) | 0 | |
Crohn’s disease treatment information at baseline, n (%) | ||||
Any Crohn’s disease treatment | 441 (88.4%) | 161 (84.3%) | 280 (90.9%) | 0.0308 |
Immunomodulators | 207 (41.5%) | 78 (40.8%) | 129 (41.9%) | 0.8179 |
Anti-TNF agents | 164 (32.9%) | 50 (26.2%) | 114 (37.0%) | 0.0123 |
Aminosalicylates | 103 (20.6%) | 47 (24.6%) | 56 (18.2%) | 0.0847 |
Steroids | 99 (19.8%) | 53 (27.7%) | 46 (14.9%) | 0.0005 |
Enteral nutrition | 69 (13.8%) | 6 (3.1%) | 63 (20.5%) | < 0.0001 |
Antibiotics | 65 (13.0%) | 6 (3.1%) | 59 (19.2%) | < 0.0001 |
Anti-tuberculosis | 27 (5.4%) | 1 (0.5%) | 26 (8.4%) | < 0.0001 |
Anti-hepatitis | 3 (0.6%) | 2 (1.0%) | 1 (0.3%) | 0.5613 |
Other agentsa | 115 (23.0%) | 7 (3.7%) | 108 (35.1%) | < 0.0001 |